Novo Nordisk (NOVO-B.CO) Stock Analysis & AI Equity Report
Novo Nordisk (NOVO-B.CO) overview
Novo Nordisk (NOVO-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Novo Nordisk reported revenue of DKK 309,064m and operating profit of DKK 127,658m; the year-end share price was 325.25 DKK and market capitalisation was DKK 1,445,086m. Novo Nordisk is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Novo Nordisk's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Novo Nordisk
Novo Nordisk is a Denmark-based global healthcare company focused on discovering, developing and delivering medicines and delivery systems for diabetes, obesity, rare blood disorders and other chronic diseases. Its portfolio includes insulin, GLP-1 treatments and injection devices, supported by research, manufacturing and global access programs. The company is also streamlining operations to refocus resources on core growth areas.
Generate the Novo Nordisk report
Novo Nordisk is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Novo Nordisk and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.